Prothena

Prothena

Yahoo Finance • 20 days ago

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Alzheimer's Disease International ("ADI") observes Sept. 21 as World Alzheimer's Day, while September is marked as World Alzheimer's Month to raise awareness about Alzheimer's disease (AD) and other forms of dementia. The 2026 campaign — T... Full story

Yahoo Finance • 2 months ago

Real Parkinson’s Disease Hope from Jupiter Neurosciences

By Mike Sheikh Parkinson's Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate.   The market isn't recognizing the story yet... Full story

Yahoo Finance • 2 months ago

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

Prothena Corporation PRTA reported second-quarter 2026 adjusted loss per share (excluding restructuring costs) of 32 cents, narrower than the Zacks Consensus Estimate of a loss of 39 cents per share. In the year-ago quarter, the company h... Full story

Yahoo Finance • 5 months ago

Prothena Reports First Quarter 2026 Financial Results and Business Highlights

Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates projected full year 2026 net cash used in operating... Full story

Yahoo Finance • 5 months ago

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Coramitug is being evaluated by Novo Nordisk in the ongoing Phase 3 CLEOPATTRA clinical trial in ~1280 participan... Full story

Yahoo Finance • 7 months ago

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

DUBLIN, March 21, 2026--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced p... Full story

Yahoo Finance • 7 months ago

Prothena authorizes up to $100 million share repurchase plan

* Prothena Corporation (PRTA [https://seekingalpha.com/symbol/PRTA]) on Friday said that its board had authorized a share repurchase plan of up to $100 million of the company’s outstanding ordinary shares. * The biotechnology company s... Full story

Yahoo Finance • 7 months ago

Prothena Announces up to $100 Million Share Repurchase Plan

DUBLIN, February 27, 2026--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announce... Full story

Yahoo Finance • 8 months ago

Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million Prothena expects the full... Full story

Yahoo Finance • 11 months ago

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash position was $331.7 million Roche to initiate... Full story

Yahoo Finance • 12 months ago

Prothena Corporation plc (PRTA): A Bull Case Theory

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 High-Potential Small-Caps With Market Cap Under $1B. We came across a bullish thesi... Full story

Yahoo Finance • last year

Bristol Myers Alzheimer's Drug Earns FDA Fast Track

This article first appeared on GuruFocus. Bristol Myers Squibb (NYSE:BMY) just got a boost in its Alzheimer's program after the FDA granted Fast Track designation to its experimental drug BMS-986446, now in phase 2 testing for patients in... Full story

Yahoo Finance • last year

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease

Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fast Track Designation recognizes the potential of anti-MTBR tau to be an important treatment... Full story

Yahoo Finance • last year

Prothena’s SWOT analysis: stock outlook shifts amid pipeline changes

Prothena Corporation plc (NASDAQ:PRTA), a biotechnology company focused on developing novel therapies for neurodegenerative and rare peripheral amyloid diseases, has experienced significant shifts in its pipeline and market outlook. With a... Full story

Yahoo Finance • last year

Novo Nordisk boosts Prothena on plans for amyloidosis therapy

[New Nordisk] hapabapa/iStock Editorial via Getty Images * Prothena (NASDAQ:PRTA [https://seekingalpha.com/symbol/PRTA]) shares spiked on Wednesday after Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) during its Q2 earnings ca... Full story

Yahoo Finance • last year

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Novo Nordisk successfully completed a Phase 2 trial with coramitug and is expected to initiate a Phase 3 program... Full story

Yahoo Finance • last year

Life360 Reaches Analyst Target Price

In recent trading, shares of Life360 Inc (Symbol: LIF) have crossed above the average analyst 12-month target price of $76.12, changing hands for $76.93/share. When a stock reaches the target an analyst has set, the analyst logically has... Full story

Yahoo Finance • last year

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Net cash used in operating and investing activities was $46.4 million in the second quarter and net cash used in operating and investing activities was $99.8 million for the first six months of 2025; quarter-end cash and restricted cash po... Full story

Yahoo Finance • last year

Prothena announces 63% workforce reduction following birtamimab halt

Prothena Corporation plc (NASDAQ:PRTA) announced a significant workforce reduction of approximately 63% to substantially reduce operating costs following its decision to discontinue development of birtamimab, according to an SEC filing on... Full story

Yahoo Finance • last year

Prothena to lay off 63% of workforce, revises full year guidance

* Prothena (NASDAQ:PRTA [https://seekingalpha.com/symbol/PRTA]) has initiated an around 63% reduction in its workforce to substantially reduce its operating costs to those necessary to support its remaining wholly owned programs, its obl... Full story